Predictive Oncology Inc.
POAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.15 | 0.28 | 5.25 | 0.47 |
| FCF Yield | -17.84% | -6.67% | -3.78% | -1.69% |
| EV / EBITDA | -6.68 | -16.18 | -22.76 | -62.02 |
| Quality | ||||
| ROIC | -560.47% | -109.55% | -118.62% | -48.00% |
| Gross Margin | 49.12% | 62.57% | 66.45% | 65.72% |
| Cash Conversion Ratio | 1.10 | 1.10 | 0.48 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.55% | 4.64% | 6.33% | 0.21% |
| Free Cash Flow Growth | 9.43% | -2.84% | 2.47% | -4.38% |
| Safety | ||||
| Net Debt / EBITDA | -0.14 | 0.51 | 1.57 | 2.25 |
| Interest Coverage | 0.00 | 0.00 | -2.44 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.14 | 1.27 | 1.17 | 1.26 |
| Cash Conversion Cycle | -166.95 | -448.96 | -290.38 | -384.22 |